



**HAL**  
open science

## Comparative study of biological versus synthetic prostheses in the treatment of ventral hernias classified as grade II/III by the Ventral Hernia Working Group

A. Herrero, M. Gonot Gaschard, H. Bouyabrine, J. Perrey, Marie-Christine C Picot, F. Guillon, J.-M. Fabre, R. Souche, F. Navarro

### ► To cite this version:

A. Herrero, M. Gonot Gaschard, H. Bouyabrine, J. Perrey, Marie-Christine C Picot, et al.. Comparative study of biological versus synthetic prostheses in the treatment of ventral hernias classified as grade II/III by the Ventral Hernia Working Group. *Journal of Visceral Surgery*, 2022, 159 (2), pp.98-107. 10.1016/j.jviscsurg.2021.02.011 . hal-03655536

**HAL Id: hal-03655536**

**<https://hal.umontpellier.fr/hal-03655536>**

Submitted on 22 Jul 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Copyright

# Comparative study of biological versus synthetic prostheses in the treatment of ventral hernias classified as grade II/III by the Ventral Hernia Working Group

Short title: Bioprotheses & Ventral Hernias VHWG II/III

**Astrid Herrero<sup>a</sup>, Mathieu Gonot Gaschard<sup>a</sup>, Hassan Bouyabrine<sup>a</sup>, Jérôme Perrey<sup>b</sup>, Marie-Christine Picot<sup>c</sup>, Françoise Guillon<sup>d</sup>, Jean-Michel Fabre<sup>d</sup>, Régis Souche<sup>d</sup>, Francis Navarro<sup>a</sup>**

- a. Department of digestive surgery and liver transplantation, University of Montpellier, hôpital Saint Eloi, CHU de Montpellier, 34295 Montpellier, France.
- b. Pharmacie Euromédecine, CHU de Montpellier, Correspondant Local de Matériovigilance, Equipe des Dispositifs Médicaux Stériles, 34295 Montpellier, France.
- c. Clinical research and epidemiology unit, Department of Medical Information, hôpital de la Colombière, CHU de Montpellier, 34295 Montpellier, France.
- d. Department of digestive surgery, University of Montpellier, hôpital Saint Eloi, CHU de Montpellier, 34295 Montpellier, France.

**Auteur correspondant :**

**Dr Astrid Herrero, MCU-PH, PHD**

Université de Montpellier  
Department of digestive surgery and liver transplantation  
Hôpital Saint Eloi, 80 avenue Augustin Fliche  
34295 Cedex 5 Montpellier  
Adresse mail : a-herrero@chu-montpellier.fr

## Summary

**AIM OF THE STUDY:** The implantation of biological prostheses in an at-risk environment has seen increasing use. Their markedly higher cost compared to synthetic prostheses makes it important to analyze their usefulness in terms of actual benefit and cost-effectiveness. This study aims to examine the relevance of bioprostheses during surgical repair of Grade II/III ventral hernias as classified by the Ventral Hernia Working Group (VHWG).

**MATERIALS AND METHODS:** This study analyzed the data of 119 patients requiring non-emergency repair of VHWG II/III grade hernias between 2010 and 2017. The results of patients who were treated with a bioprosthesis (n = 59) were compared to those receiving a synthetic prosthesis (n = 60). The primary outcome was surgical site infection (SSI) at 90 days. The secondary endpoints were hernia recurrence rate, cost of the prosthesis, duration of hospital stay and re-hospitalization rate.

**RESULTS:** The two groups were shown to be comparable by analysis of demographic, pre- and intra-operative data. The SSI rate was significantly higher in the bioprosthesis group (20% vs. 7%; p = 0.010), as was the recurrence rate (56% vs. 28%; p = 0.003) with a median follow-up of 40.15 months. The cost of the bioprosthesis was significantly higher than that of the synthetic prosthesis (€ 3363 vs. € 249; p <0.010).

**CONCLUSION:** In this retrospective study, the use of a bioprosthesis for repair of VHWG II/III ventral hernias was associated with a higher rate of both SSI and hernia recurrence at a cost 13 times greater than the use of a synthetic prosthesis.

**Keywords:** Biological prosthesis, Parietal reconstruction, Grade II/III ventral hernia, SSI, Recurrence

## Essential points

- The management of ventral hernia in patients at risk of septic complications is poorly codified.
- The most important risk after prosthetic repair of abdominal wall hernia is surgical site infection (SSI).
- The development of bioprosthesis has offered hope of decreasing the risks of SSI or recurrence in contaminated, clean-contaminated or at-risk of contamination, operative settings, but at a very high cost.
- The results of our study showed bioprosthesis to have a low efficacy in preventing SSI in patients at septic risk and they are associated with a significant medium-term risk of recurrence.
- The use of bioprosthesis must be reconsidered and should probably be limited to exceptional situations which must be defined in terms of patient and societal benefit.

## Introduction

The surgical management of ventral hernias is a complex issue that has led to the evaluation of the benefit of the prophylactic placement of a prosthesis during the closure of a midline laparotomy in at-risk patients (1). The many surgical techniques and multiple available types of synthetic and biological prostheses have led to heterogeneous studies with contradictory results (2,3). There is currently no consensus on the management of ventral hernias, and treatment methods vary among surgeons. In 2008, the Cochrane Database published a systematic review analyzing the different repair techniques, with or without prosthesis, as well as the different implantation sites, and was unable to issue a formal recommendation (4). The only point of consensus is that repair with prosthesis implantation reduces the rate of late hernia recurrence (5,6). Some teams go so far as to question the value of surgical management compared to simple monitoring (7). The most feared post-operative complication is infection of the prosthesis, whose prevalence varies between 5 and 10% in some studies, or even more than 30% depending on the presence of contamination or intra-operative infection (8-12). Biological prostheses constructed from porcine or bovine dermis with or without collagen cross-linking (reticulation) have been developed and marketed with the aim of reducing the incidence of prosthetic infection. The initial concept was that their matrix of biological origin would be integrated into the native tissue and allow better resistance to bacterial contamination. Clinical trials in animals supported this hypothesis, showing better bacterial clearance compared to polytetrafluoroethylene (PTFE) prostheses (13). Their use has increased in recent years, mainly for implantation in a contaminated or clean-contaminated environment, or when the risk of infection is considered high. In 2010, the Ventral Hernia Working Group published recommendations for hernia repair techniques tailored to their four grades of classification shown in Figure 1. These recommendations, based on studies with a low level of evidence, proposed use of biological prostheses for Grade II (patients with co-morbidities) [3]. Like many recommendations, even though they

are of weak scientific evidence, they have been widely referenced and have been followed in clinical practice. However, studies have shown conflicting results on their benefit in preventing SSI, as well as their long-term effectiveness in preventing the risk of hernia recurrence (14,15). In view of their cost, which is markedly higher than that of PTFE prostheses, it is important to rigorously analyze their usefulness in terms of actual benefit for the patient and for society. The objective of this study was to compare the post-operative results after implantation of a biological versus synthetic prosthesis during ventral hernia repair in patients at risk of septic complication (VHWG Grade II and III) (3,16).

## **Patients and Method**

This is a retrospective, monocentric, comparative cohort study, based on the type of prosthesis implanted (biological or synthetic) during ventral hernia repair at the two digestive surgery departments of the University Hospital of Montpellier between January 1, 2010 and December 31, 2017. This study was conducted as part of an assessment of professional practices in our operating rooms. Only patients with a ventral hernia at increased risk of infection, VHWG grade II or III (3,16) were included. The data of patients who were treated with a biological prosthesis (Pbio group) or synthetic (Psyn group) were compared. Patients with grade I or IV ventral hernia and those undergoing emergency surgery were excluded. Data collection was carried out retrospectively after approval by the establishment's ethics committee (IRB no. 2019\_IRB-MTP\_06-09), using the data available in the patient's computerized medical file *via* our institution's software (Dx Care®). Demographic data (age, sex, BMI, ASA score) as well as medical history (diabetes, COPD, smoking, alcohol consumption, immunosuppressive treatment, type of initial intervention, context of recurrent ventral hernia) were collected and compared.

## ***Surgeries***

The surgical data were collected from the operative report: the type of hernia surgery (midline, subcostal, transverse, peristomal), the diameter in cm of the hernia neck, the type and size of prosthesis used and the type of repair (onlay, sublay, underlay and inlay). The choice of the type of prosthesis was left to the discretion of the operating surgeon since there was no defined treatment protocol at our center. Drains were placed according to the surgeons' preferences, and generally removed between the third and fifth post-operative day if drainage was less than 50cc/24h. All procedures were performed by laparotomy in these VHWG II/III patients.

### ***Post-operative follow-up***

Follow-up data were obtained from the various consultation letters and examination results available. Data concerning duration of stay and the rate of unscheduled re-hospitalization were collected.

Morbidity and mortality data were collected up to 90 days after the operation, and classified according to Clavien-Dindo (17). Typically, follow-up consisted of a systematic follow-up visit with the surgeon at one month and at three months after the operation.

Recurrence was assessed by clinical examination, possibly confirmed by an imaging study in case of clinical doubt (ultrasound or uninjected abdomino-pelvic CT). For patients who were not available for follow-up visit, a telephone interview was carried out at the time of the study to find out whether they had developed a recurrence and, if so, its time to onset and whether it had required surgery.

The costs for prosthetic implants were provided by the pharmacist of the service.

### ***Outcome measures***

The primary outcome measure was the rate of SSI at 90 days after the operation, defined by the presence of a local infection around the prosthesis resulting in abscess, generalized sepsis or purulent discharge from the wound.

Secondary endpoints included the hernia recurrence rate, the cost of the prosthesis, duration of stay and re-hospitalization rate.

### ***Statistical analysis***

Statistical analysis was carried out by the Department of Medical Information of the University Hospital of Montpellier using SAS® Version 7.12 HF4 software. Quantitative variables were described by their number with mean and standard deviation, or by their median with 1st and 3rd quartiles and range (minimum and maximum). Qualitative variables were described by their frequency and the percentage of patients in each category. Missing data was not considered in the calculation of the percentages.

Two groups were studied: the biological prosthesis (PBio) group and the synthetic prosthesis (PSyn) group. Comparison between the groups was established by the Chi-square or Fisher's tests for qualitative variables and by the Student's or Wilcoxon and Mann-Whitney tests for quantitative variables. The results for the primary endpoint, SSI, were analyzed using a univariable and multivariable logistic regression model. They are expressed as Odds Ratio with 95% confidence interval, adjusted for the ASA score and the type of prosthesis. All statistical tests were two-tailed with a Type I error of 0.05. Recurrent hernia and interval to recurrence were represented according to the Kaplan-Meier method and compared between the two groups according to the Log Rank test.

## **Results**

### ***Descriptive analysis of populations and surgical interventions***

Between January 1, 2010 and December 31, 2017, 563 patients underwent ventral hernia repair with placement of a parietal prosthesis at the University



Hospital of Montpellier. Among them, 441 patients received a synthetic prosthesis (78.3%) and 122 received a biological prosthesis (21.6%). In our study, 119 patients who met the inclusion criteria were analyzed. For these patients, 59 patients received a biological prosthesis (PBio group) and 60 patients received a synthetic prosthesis (PSyn group). The flow diagram is summarized in Figure 2. The distribution by VHWG Grade was similar between the two groups, including the patients classified VHWG II (28 (47.5%) versus 29 (48.3%);  $p = 0.924$ ) and the patients classified VHWG III (31 (52.5%) versus 31 (51.7%);  $p = 0.924$ ). Patient demographics, co-morbidities and surgical characteristics of the procedures were analyzed and compared between the two groups. Apart from the ASA score, which was significantly higher in the PBio group compared to the PSyn group (3 [1-3] versus 2 [1-4];  $p < 0.010$ ), the other demographic data were comparable in the two groups. Co-morbidity data showed no statistically significant difference between the two groups (Table 1). In the overall population studied, the two predominant indications for the initial surgery from which the ventral hernia stemmed were inframesocolic surgery in 70 patients (58.8%), 48 of whom had peristomal hernia (40%), followed by liver transplantation in 37 patients (31%). There was no significant difference between the two groups regarding the indications for the initial surgery.

The anatomical characteristics of the ventral hernia and the intra-operative data are detailed in Table 2. No statistically significant difference was found in the mean size of the hernia neck between the two groups (7.75 cm  $\pm$  5.25 versus 8.36 cm  $\pm$  7.10;  $p = 0.790$ ). In contrast, the surface area of the prosthesis used (in cm<sup>2</sup>) was significantly larger in the Pbio group (519.6  $\pm$  404.1 vs. 334.24  $\pm$  241;  $p = 0.032$ ). There was no statistically significant difference between the two groups regarding the association of the ventral hernia repair with another intervention, including colectomy, cholecystectomy and stomal transposition. The positioning of the prosthesis was comparable between the two groups, mainly in the retromuscular position (35 (63.6%) vs. 39 (65%);  $p = 0.890$ ), and intraperitoneal (17 (30.9%) vs. 20 (33, 3%);  $p = 0.780$ ). Regarding details of surgical technique, there was no statistically significant difference in terms of the

use of a component separation technique, implantation of a bridging prosthesis, drainage, or placement of a compression bandage. Note that there were more bridging prostheses in the PBio group although this was not statistically significant (3 (5.45%) versus 0 (0%);  $p = 0.106$ ). Three types of biological prostheses were used (CELLIS® (reticulated porcine dermis, Mecellis-La Rochelle- France;  $n = 38$ ), PERMACOL® (reticulated porcine dermis, Covidien / Medtronic-Minneapolis, USA;  $n = 12$ ), TUTOMESH® (non-reticulated bovine pericardium, Novomedics-Metz- France;  $n = 9$ )). Nine types of synthetic prosthesis were used in this study (PROLENE®  $n = 17$ ; PHYSIOMESH®  $n = 17$ ; PARIETEX®  $n = 9$ ; VENTRAL PATCH®  $n = 5$ ; PROGRIP®  $n = 5$ ; PROCEED®  $n = 3$ ; TIMESH®  $n = 2$ ; PROMESH®  $n = 1$ ; ABSOLIGHT®  $n = 1$ ).

### ***Post-operative results***

The post-operative results are detailed in Table 3. There was no statistically significant difference in parietal complications in terms of hematoma, seroma, skin necrosis and evisceration. There was more wound dehiscence in the PBio group (8 (13.5%) vs. 0 (0%);  $p = 0.030$ ). The severity of complications was greater in the PBio group, with more Clavien 3-4 complications (14 (23.7%) vs. 4 (6.6%);  $p = 0.009$ ). More of the complications in the PSyn group underwent simple monitoring than in the PBio group (5 (45.4%) vs. 1 (5%);  $p = 0.013$ ).

Other types of management (revisional surgery, antibiotic therapy, radiological drainage, local wound care or VAC therapy) were not statistically significantly different in the two groups.

### ***Primary endpoint results***

The SSI rate was significantly higher in the PBio group (12 (20.3%) vs. 4 (6.6%);  $p = 0.014$ ). In multivariable analysis (Table 4), the variables that were independently associated with SSI were: diabetes (OR: 4.127 (1.009-16.875);  $p = 0.048$ ), use of a biological prosthesis (OR: 4.585 (1.167–18.001);  $p = 0.029$ ) and

performance of a colectomy in association with the ventral hernia repair (OR: 38.381 (2.186-673.843);  $p = 0.01$ ).

Retromuscular positioning of the prosthesis was a protective factor (OR: 0.287 (0.089-0.925);  $p = 0.03$ ).

### *Secondary endpoint results*

#### *Duration of stay and cost of the prosthesis*

The total duration of stay was significantly longer in the PBio group (median 7 days [1-28] vs. 5 days [1-29];  $p = 0.001$ ). The length of stay in intensive care or continuing care was not statistically different in the two groups. The readmission rate was statistically significantly higher in the PBio group (10 (16.9%) vs. 2 (3.3%);  $p = 0.013$ ). The average cost of the prosthesis was statistically significantly higher in the PBio group (€ 3,363.34 ( $\pm$  € 2,355.08) vs. €249.44 ( $\pm$  € 187.76);  $p < 0.001$ ).

#### *Recurrent ventral hernia*

After a median follow-up of 36.5 months (3-105 months) with five patients lost to follow-up (one in the PSyn group, four in the PBio group), 48 patients developed recurrence of their ventral hernia (40%) within a median interval of ten months (1-30 months). The number of recurrences was statistically significantly greater in the PBio group compared to the PSyn group (31 (56.36%) vs. 17 (28.8%);  $p = 0.002$ ).

These results were confirmed by analysis of recurrence-free survival, which was significantly lower in the PBio group ( $p = 0.001$ ) (Figure 3). Among these patients, 23 (48%) were re-operated, including 11 in the PBio group and 12 in the PSyn group.

## **Discussion**

This study leads us to express strong cautions about the effectiveness of biological prostheses in patients with VHWG Grade II/III hernias, in view of the higher rate of SSI (20%), with longer hospital stay, higher rehospitalization rate and medium-term recurrence rate (> 50%) compared to patients who had implantation of a synthetic prosthesis. When these disappointing results are coupled to an additional material cost 13 times greater than that of synthetic material, we must question the medico-economic interest of continuing to use bioprosthetic material. The short and medium term results of this study are in agreement with other data available in the literature (18,19).

In 2015, Abdelfatah *et al.* published a study reporting the long-term results of Permacol® bioprostheses with a follow-up of more than five years. The surgical site infection rate in their series was 20% for all VHWG classes combined, with a 66% overall rate of clinically confirmed recurrence (18).

In 2016, Majmunder *et al.* conducted a retrospective multicenter comparative study comparing biological and synthetic prostheses with regard to infection risk and recurrence rate (19). Their results also demonstrated a higher SSI rate in the PBio group (31.9% vs. 12.3%,  $p = 0.01$ ), as well as a higher 1-year recurrence rate compared to the PSyn group (26.3% vs. 8.9%,  $p = 0.039$ ).

More recently, Baldan *et al.* published a retrospective multicenter study to present the results of biological prostheses in northeastern Italy (20). Although there was no comparison with synthetic prostheses, they showed SSI rates of only 8.9% and 14.3% in VHWG II and III classes respectively. This infection rate seems low compared to our study and the other studies discussed above. Since their definition of infection was not precisely explained in their methodology and was perhaps more restrictive than the one we used, it is possible that this explains the complication rates of 32.4% and 36.6% in the VHWG II and III groups, respectively, including hematomas, seromas and enterocutaneous fistulas; this is lower than in our experience.

Their study has the theoretical advantage of its multicenter nature, but there appears to be a significant evaluation bias. In fact, the data was collected by each center and then sent to the center performing the study, which centralized

the results received and requested additional information by e-mail if necessary. It is therefore possible that the complications were underestimated.

In our study, which is an evaluation of professional practices, the rate of active smoking in the population was high (43.3% in the PSyn group vs. 49% in the PBio group, no statistically significant difference). However, active smoking is a known risk factor for SSI due to decreased tissue oxygenation and interference with the healing process (21-23). Several randomized trials and a meta-analysis have demonstrated that smoking cessation at least four weeks before surgery is beneficial in reducing the number of post-operative infections (24-26). Tobacco usage and obesity (21) are the only modifiable risk factors pre-operatively and the surgeon must address them before proposing parietal repair in order to improve results.

With regard to hernia recurrence, we found a high recurrence rate in our study regardless of the type of prosthesis used (56.36% vs. 28.81%,  $p = 0.029$ ), which is probably related to the SSI rate. In fact, the vicious circle of "wall repair, complication, recurrence, re-operation" is well described in the literature, and it is known that SSI doubles the risk of hernia recurrence (27). On the other hand, other facts that may explain our high recurrence rate include the fact that

(i) our population included –a large number of hepatic and/or renal transplant patients on immunosuppressants that may promote recurrence, as well as patients with peri-stomal hernia whose management is complex and often a source of recurrence,

(ii) the evaluation of recurrence was somewhat subjective for patients who were lost to follow-up or who were not seen in follow-up consultation due to lack of symptoms. These patients were queried by telephone regarding hernia recurrence; for this reason, interpretation of this rate is subject to caution. Our high recurrence rate, regardless of the repair technique, reflects a reality that is supported by the publication of an international multicenter prospective cohort study that included 1075 patients and revealed a recurrence rate at two years of 27.7% (28). Risk factors identified were a past history of hernia repair, lateral

herniation, concomitant intestinal surgery, the occurrence of post-operative complications and the absence of a prosthesis.

This study has several limitations.

Our cohort study is retrospective and monocentric but the limited number of patients makes any matching difficult, even though—the numbers were large compared to other studies on the subject. This cohort remains heterogeneous, including patients with several types of prostheses, associated surgical procedures, different sites of herniation and different techniques of hernia repair. The fact that the ASA score is higher in the PBio group may call into question whether the two groups are truly comparable, due to patient selection bias. ASA score assessment remains subjective and variable depending on the anesthesiologist's interpretation. In order to reduce this potential bias, multivariable analysis with adjustment of the Odds-Ratio calculation on the ASA score was performed and still found a statistically significant difference in the SSI risk depending on the type of prosthesis.

We also emphasize that the only independent protective factor for SSI is implantation of the prosthesis in the retromuscular position. The pre-operative choice of parietal repair technique and evaluation of its feasibility remains essential for the success of surgical management.

Our evaluation of economic impact considers only the cost of the prosthetic patch without considering other associated hospital costs. Yet, duration of stay as well as the number of readmissions were also higher in the PBio group. These results call into question whether use of a bioprosthesis is indicated in VHWG Grade II/III patients. It is very likely that the septic risk of hernia repairs with synthetic prosthesis was overestimated in these patients, especially in those where only the site-related risk factors were retained. Only the results of ongoing randomized trials (SIMBIOSE, MEMBO) will allow us to assess the role of bioprostheses in our therapeutic arsenal (29). In addition, the communication of our results within our center has directly impacted our clinical practices by decreasing our indications for the placement of biological prostheses, which are currently reserved only for situations where there are no other alternatives.

Finally, the occurrence of SSI within 90 post-operative days after placement of a biological prosthesis should probably not be considered a complication in itself. While biological prostheses were placed for curative purposes in this study, they could also be reconsidered as a delaying tactic or first stage treatment in these high-risk patients. The PBio participates in the healing of chronic parietal infection before re-operation using a non-absorbable synthetic prosthesis. The role of PBio in the arsenal of prostheses would therefore be similar to absorbable synthetic prostheses, *i.e.* Vicryl®, which are, however, much less expensive. In this setting, the need to remove the prosthesis remains low and local care of infection is often sufficient (30). The development and marketing of slowly resorbable biosynthetic prostheses (6-36 months), which are designed, in principle to disappear and be eventually replaced by solid fibrous tissue similar to neo-fascia has reopened the debate. The multicenter, prospective COBRA study, which included 104 patients with large eventrations, has shown the effectiveness of these prostheses for repairs in clean-contaminated and contaminated environments with a 2-year hernia recurrence rate of 17% (31). These very encouraging results were also found in a French prospective study concerning complex parietal repairs with a one-year recurrence rate of 10.3%, equivalent to the results of synthetic prostheses in a clean environment (32).

## **Conclusion**

The results of this study reinforce other studies the literature and provide additional arguments for limiting the use of bioprostheses to exceptional situations where there is a severe risk of infection (VHWG grade 4). It appears that bioprostheses are not as effective as hoped in preventing SSIs and are also associated with high medium-term recurrence rates. The ongoing development of absorbable biosynthetic prostheses, currently under evaluation, could provide an attractive alternative in our surgical arsenal in terms of cost-effectiveness.

Declaration of links of interest: The authors declare that they have no links of interest

## References

1. Bhangu A, Fitzgerald JE, Singh P, Battersby N, Marriott P, Pinkney T. Systematic review and meta-analysis of prophylactic mesh placement for prevention of incisional hernia following midline laparotomy. *Hernia*. 2013; 17(4): 445-55.
2. Gainant A, Fredon F. Chirurgie des éventrations de la paroi abdominale. *Encyclopédie médico-chirurgicale*.40(165).
3. Ventral Hernia Working G, Breuing K, Butler CE, Ferzoco S, Franz M, Hultman CS, *et al*. Incisional ventral hernias: review of the literature and recommendations regarding the grading and technique of repair. *Surgery*. 2010; 148(3): 544-58.
4. den Hartog D, Dur AH, Tuinebreijer WE, Kreis RW. Open surgical procedures for incisional hernias. *The Cochrane database of systematic reviews*. 2008(3): CD006438.
5. Luijendijk RW, Hop WC, van den Tol MP, de Lange DC, Braaksma MM, JN IJ, *et al*. A comparison of suture repair with mesh repair for incisional hernia. *N Engl J Med*. 2000; 343(6): 392-8.
6. Burger JW, Luijendijk RW, Hop WC, Halm JA, Verdaasdonk EG, Jeekel J. Long-term follow-up of a randomized controlled trial of suture versus mesh repair of incisional hernia. *Annals of surgery*. 2004; 240(4): 578-83; discussion 83-5.
7. Wolf LL, Ejiofor JI, Wang Y, Hunink MG, Losina E, Haider AH, *et al*. Management of Reducible Ventral Hernias: Clinical Outcomes and Cost-effectiveness of Repair at Diagnosis Versus Watchful Waiting. *Annals of surgery*. 2019; 269(2): 358-66.
8. Sanchez VM, Abi-Haidar YE, Itani KM. Mesh infection in ventral incisional hernia repair: incidence, contributing factors, and treatment. *Surg Infect (Larchmt)*. 2011; 12(3): 205-10.
9. Tubre DJ, Schroeder AD, Estes J, Eisenga J, Fitzgibbons RJ, Jr. Surgical site infection: the "Achilles Heel" of all types of abdominal wall hernia reconstruction. *Hernia*. 2018; 22(6): 1003-13.
10. Carbonell AM, Criss CN, Cobb WS, Novitsky YW, Rosen MJ. Outcomes of synthetic mesh in contaminated ventral hernia repairs. *J Am Coll Surg*. 2013; 217(6): 991-8.
11. Tastaldi L, Krpata DM, Prabhu AS, Petro CC, Rosenblatt S, Haskins IN, *et al*. The effect of increasing body mass index on wound complications in open ventral hernia repair with mesh. *Am J Surg*. 2019; 218(3): 560-6.



12. Pochhammer J, Scholtes B, Keuler J, Mussle B, Welsch T, Schaffer M. Serum C-reactive protein level after ventral hernia repair with mesh reinforcement can predict infectious complications: a retrospective cohort study. *Hernia*. 2020; 24(1): 41-8.
13. Milburn ML, Holton LH, Chung TL, Li EN, Bochicchio GV, Goldberg NH, *et al.* Acellular dermal matrix compared with synthetic implant material for repair of ventral hernia in the setting of peri-operative *Staphylococcus aureus* implant contamination: a rabbit model. *Surg Infect (Larchmt)*. 2008; 9(4): 433-42.
14. Gurrado A, Franco IF, Lissidini G, Greco G, De Fazio M, Pasculli A, *et al.* Impact of pericardium bovine patch (Tutomech((R))) on incisional hernia treatment in contaminated or potentially contaminated fields: retrospective comparative study. *Hernia*. 2015; 19(2): 259-66.
15. Renard Y, de Mestier L, Henriques J, de Boissieu P, de Mestier P, Fingerhut A, *et al.* Absorbable Polyglactin vs. Non-Cross-linked Porcine Biological Mesh for the Surgical Treatment of Infected Incisional Hernia. *J Gastrointest Surg*. 2020; 24(2): 435-43.
16. Kanters AE, Krpata DM, Blatnik JA, Novitsky YM, Rosen MJ. Modified hernia grading scale to stratify surgical site occurrence after open ventral hernia repairs. *J Am Coll Surg*. 2012; 215(6): 787-93.
17. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Annals of surgery*. 2004; 240(2): 205-13.
18. Abdelfatah MM, Rostambeigi N, Podgaetz E, Sarr MG. Long-term outcomes (>5-year follow-up) with porcine acellular dermal matrix (Permacol) in incisional hernias at risk for infection. *Hernia*. 2015; 19(1): 135-40.
19. Majumder A, Winder JS, Wen Y, Pauli EM, Belyansky I, Novitsky YW. Comparative analysis of biologic versus synthetic mesh outcomes in contaminated hernia repairs. *Surgery*. 2016; 160(4): 828-38.
20. Baldan N, Munegato G, Di Leo A, Lauro E, Morpurgo E, Pianigiani S, *et al.* Lessons learned from 227 biological meshes used for the surgical treatment of ventral abdominal defects. *Hernia*. 2020; 24(1): 57-65.
21. Park H, de Virgilio C, Kim DY, Shover AL, Moazzez A. Effects of smoking and different BMI cutoff points on surgical site infection after elective open ventral hernia repair. *Hernia*. 2020.
22. Dunne JR, Malone DL, Tracy JK, Napolitano LM. Abdominal wall hernias: risk factors for infection and resource utilization. *J Surg Res*. 2003; 111(1): 78-84.
23. Finan KR, Vick CC, Kiefe CI, Neumayer L, Hawn MT. Predictors of wound infection in ventral hernia repair. *Am J Surg*. 2005; 190(5): 676-81.
24. Moller AM, Villebro N, Pedersen T, Tonnesen H. Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. *Lancet*. 2002; 359(9301): 114-7.
25. Sorensen LT. Wound healing and infection in surgery. The clinical impact of smoking and smoking cessation: a systematic review and meta-analysis. *Arch Surg*. 2012; 147(4): 373-83.

26. Sorensen LT, Karlsmark T, Gottrup F. Abstinence from smoking reduces incisional wound infection: a randomized controlled trial. *Ann Surg.* 2003; 238(1): 1-5.
27. Holihan JL, Alawadi Z, Martindale RG, Roth JS, Wray CJ, Ko TC, *et al.* Adverse Events after Ventral Hernia Repair: The Vicious Cycle of Complications. *J Am Coll Surg.* 2015; 221(2): 478-85.
28. Romain B, Renard Y, Binquet C, Poghosyan T, Moszkowicz D, Gillion JF, *et al.* Recurrence after elective incisional hernia repair is more frequent than you think: An international prospective cohort from the French Society of Surgery. *Surgery.* 2020; 168(1): 125-34.
29. Moszkowicz D, Bouillot JL. Biological mesh: From concept to clinical reality. *J Visc Surg.* 2018; 155(5): 347-8.
30. Boullenois H, Moszkowicz D, Poghosyan T, Bouillot JL. Surgical management of chronic mesh infection following incisional hernia repair. *J Visc Surg.* 2016; 153(6): 461-4.
31. Rosen MJ, Bauer JJ, Harmaty M, Carbonell AM, Cobb WS, Matthews B, *et al.* Multicenter, Prospective, Longitudinal Study of the Recurrence, Surgical Site Infection, and Quality of Life After Contaminated Ventral Hernia Repair Using Biosynthetic Absorbable Mesh: The COBRA Study. *Ann Surg.* 2017; 265(1): 205-11.
32. Vauclair E, Bert M, Facy O, Cheynel N, Rat P, Ortega-Deballon P. What results can be expected one year after complex incisional hernia repair with biosynthetic mesh? *J Visc Surg.* 2020. In press Doi : 10.1016/j.jvisc Surg.2020.07.008

## Tables

**Table 1: Demographic data and characteristics of ventral hernias**

Variables	Synthetic prosthesis (n=60)	Biologic prosthesis (n=59)	P value
<i>Age, mean ± SD</i>	58.22 ± (12.2)	59.80 (± 12.4)	0.430
<i>Sex</i>			
Female	21 (36%)	22 (37%)	–
Male	76 (64%)	37 (63%)	0.800
<i>BMI, mean ± SD</i>	28 (± 6)	27 (± 6)	0.290
<i>ASA Score</i>			0.017
1	5 (8.3%)	1 (1.7%)	
2	36 (60%)	21 (35.6%)	
3	19 (31.7%)	36 (61%)	
4	0 (0%)	1 (1.7%)	
<i>Past medical history</i>			
Alcohol abuse	9 (15%)	16 (27.1%)	0.105
Active smoking history	26 (43.3%)	29 (49.2%)	0.524
Diabetes	10 (16.7%)	9 (15.3%)	0.833
Immunosuppression	29 (48.3%)	24 (40.7%)	0.401
Inflammatory bowel disease	8 (13.3%)	5 (8.5%)	0.396
Cirrhosis	2 (3.3%)	7 (11.9%)	0.095
Chronic renal insufficiency	6 (10%)	6 (10.2%)	0.976
Obesity	18 (30%)	18 (30.5%)	0.952
Chronic obstructive pulmonary disease	16 (26.7%)	14 (24.1%)	0.753
Cardiovascular risk factors	60 (100%)	59 (100%)	0.407
Malnutrition	0 (0%)	1 (1.7%)	0.496
<i>VHWG grade</i>			
Grade II	29 (48.3%)	28 (47.5%)	–
Grade III	31 (51.7%)	31 (52.5%)	0.924
<i>Risk factors for infection</i>			
Peristomal hernia	24 (40.0%)	24 (40.7%)	0.941
Past history of liver transplantation	19 (31.7%)	18 (30.5%)	0.891
Past history of renal transplantation	6 (10%)	3 (5.1%)	0.491
Associated cholecystectomy	4 (6.7%)	3 (5.1%)	1.000

Ventral hernia with transposition of stoma	3 (5.00)	0 (0%)	0.244
Associated colectomy	2 (3.3%)	1 (1.7%)	1.000

---

SD: Standard Deviation; BMI: Body Mass Index; ASA: American Society of Anesthesiologists; VHWG: Ventral Hernia Working Group

**Table 2: Intra-operative data**

<b>Intra-operative data</b>	Synthetic prosthesis (n=60)	Biologic prosthesis (n=59)	<i>P</i> value
<i>Type of ventral hernia</i>			
Midline incisional hernia	21 (35%)	16 (27%)	0.353
Sub-costal incisional hernia	13 (21%)	18 (30%)	0.272
Transverse incisional hernia	7 (11%)	3 (5%)	0.322
<i>Hernia dimensions</i>			
Hernia neck (cm), mean $\pm$ SD	7.8 ( $\pm$ 5.3)	8.4 ( $\pm$ 7.1)	0.787
Size of prosthesis (cm <sup>2</sup> ), mean $\pm$ SD	334.24 ( $\pm$ 241)	519.6 ( $\pm$ 404)	<b>0.032</b>
<i>Localization of prosthesis placement</i>			
Onlay	0 (0%)	1 (1.8%)	0.478
Sublay	39 (65%)	35 (63.6%)	0.879
Underlay	20 (33.3%)	17 (30.9%)	0.781
Inlay	1 (1.6%)	0 (0%)	1.000
<i>Cost of prosthesis (Euros), mean <math>\pm</math> SD</i>	€ 249 ( $\pm$ 188)	€ 3363 ( $\pm$ 2355)	<b>&lt;0.0001</b>

**Table 3: Post-operative results**

Complications	Synthetic prosthesis (n=60)	Biologic prosthesis (n=59)	P value
<i>Local complications</i>	11 (18.3%)	20 (33.9%)	0.062
Hematoma	4 (6.7%)	2 (3.4%)	0.679
Wound dehiscence	0 (0%)	8 (13.6%)	<b>0.003</b>
Skin necrosis	0 (0%)	4 (6.7%)	0.057
Seroma	4 (6.7%)	3 (5.1%)	1.000
Evisceration	2 (3.3%)	1 (1.7%)	1.000
<i>Surgical site infection</i>	4 (6.6%)	12 (20.3%)	<b>0.030</b>
Superficial infection	1 (1.67%)	2 (3.3%)	1.000
Deep abscess	3 (5%)	10 (16.9%)	<b>0.037</b>
<i>Surgical re-intervention</i>	3 (5%)	6 (10.1%)	0.322
<i>Removal of the prosthesis</i>	1 (1.6%)	2 (3.3%)	0.619
<i>Clavien-Dindo Classification</i>			
no complications	44 (73.3%)	34 (57.6%)	0.071
Clavien 1-2	11 (18.3%)	11 (18.6%)	0.965
Clavien 3-4	4 (6.6%)	14 (23.7%)	<b>0.009</b>
Clavien 5	0 (0%)	0 (0%)	-
<i>Hospital stay</i>			
Total hospital stay (days) median [range]	5 [1-29]	7 [1-28]	<b>0.001</b>
ICU stay (days), mean ± SD	0.17 (±0.67)	0.44 (±2.30)	0.744
Non-ICU stay (days), mean ± SD	1.25 (±3.18)	1.49 (±2.69)	0.226
<i>Unscheduled rehospitalization</i>	2 (3.33%)	10 (16.95%)	<b>0.013</b>

**Table 4: Univariable and multivariable analysis of risk factors for surgical site infection (SSI)**

Variables	No SSI (n=103) n(%)	SSI (N=16) n(%)	Odds Ratio (OR) (95% CI)	p	OR adjusted for ASA, type of prosthesis (95% CI)	p
<i>Age (Mean ±SD)</i>	59.22 (±11.87)	57.56 (±14.97)	0.989 (0.949 – 1.032)	0.85	0.997 (0.952 - 1.045)	0.91
<i>Sex</i>			0.778 (0.251 – 2.408)	0.66	0.854 (0.259 - 2.814)	0.80
Female (N, %)	38 (36.89)	5 (31.25)				
Male (N, %)	65 (63.11)	11 (68.75)				
<i>BMI (Mean ± SD)</i>	27.75 (±5.74)	27.75 (±6.33)	0.951 (0.369 – 2.451)	0.88	1.075 (0.411- 2.811)	0.88
<i>ASA Score</i>			1.532 (0.530 – 4.426)	0.43	.	.
1-2 (N, %)	56 (54.37)	7 (43.75)				
3-4 (N, %)	47 (45.63)	9 (56.25)				
<i>Past Medical History</i>						
Alcohol abuse	22 (21.36)	3 (18.75)	0.850 (0.222 – 3.248)	1.00	0.712 (0.178 - 2.855)	0.63
Active smoking	49 (47.57)	6 (37.50)	0.661 (0.224 – 1.954)	0.45	0.650 (0.206 - 2.055)	0.46
Diabetes	14 (13.59)	5 (31.25)	2.890 (0.872 – 9.575)	0.13	4.127 (1.009 - 16.875)	<b>0.048</b> 5
Immunosuppression	45 (43.69)	8 (50.00)	1.289 (0.449 – 3.700)	0.64	1.226 (0.397 - 3.782)	0.72
Inflammatory bowel disease	9 (8.74)	4 (25.00)	3.482 (0.928 – 13.062)	0.07	3.237 (0.692 - 15.148)	0.14
Cirrhosis	8 (7.77)	1 (6.25)	0.792 (0.092 – 6.790)	1.00	0.542 (0.059 - 4.936)	0.59
Chronic renal insufficiency	10 (9.71)	2 (12.50)	1.329 (0.263 – 6.706)	0.66	1.431 (0.264 - 7.768)	0.68
Obesity	29 (28.16)	7 (43.75)	1.985 (0.676 – 5.827)	0.25	1.656 (0.519 - 5.282)	0.39
Chronic obstructive pulmonary disease	27 (26.21)	3 (20.00)	0.704 (0.184 – 2.686)	0.76	0.794 (0.198 - 3.186)	0.75
Cardiovascular risk factors	54 (52.43)	8 (50.00)	0.907 (0.316 – 2.602)	0.86	0.899 (0.282 - 2.865)	0.86
Malnutrition	1 (0.97)	0 (0.00)	.	.	.	.
History of liver transplant	33 (32.04)	4 (25.00)	0.707 (0.212 – 2.359)	0.77	0.759 (0.214 - 2.686)	0.67
History of renal transplant	8 (7.77)	1 (6.25)	0.792 (0.092 – 6.790)	1.00	1.053 (0.108 - 10.273)	0.96
<i>Type of prosthesis</i>						
Synthetic	57 (54.81)	3 (20.00)	4.851 (1.292 – 18.210)	<b>0.01</b>	4.585 (1.167 – 18.017)	<b>0.029</b>
Biologic	47 (45.19)	12 (80.00)				

<i>Ventral hernia location</i>	32 (31.07)	5 (31.25)	1.009 (0.324 – 3.142)	1.00	1.339 (0.402 - 4.461)	0.63
Midline						
Subcostal	27 (26.21)	4 (25.00)	0.938 (0.279 – 3.158)	1.00	0.885 (0.251 - 3.124)	0.85
Peristomal	40 (38.83)	8 (50.00)	1.575 (0.547 – 4.533)	0.40	1.352 (0.441 - 4.144)	0.60
Transverse	10 (9.71)	0 (0.00)	.	.	.	.
<i>VHWG 2/3</i>			0.612 (0.207 – 1.807)	0.37	1.270 (0.570 - 2.831)	0.55
2 (N, %)	51 (49.51)	6 (37.50)				
3 (N, %)	52 (50.49)	10 (62.50)				
<i>Ventral hernia repair with stomal transposition</i>	3 (2.91)	0 (0.00)	.	.	.	.
<i>Associated colectomy</i>	1 (0.97)	2 (12.50)	14.560 (1.239 – 171.159)	<b>0.05</b>	38.381 (2.186 - 673.843)	<b>0.01</b>
<i>Hernia neck diameter (cm): Median (range)</i>	5.00 (3.00 ; 10.00)	8.00 (5.00 ; 20.00)	1.069 (0.991– 1.154)	0.07	1.060 (0.980 - 1.147)	0.14
Onlay	1 (1.01)	0 (0.00)	.	.	.	.
Inlay	0 (0.00)	1 (6.25)	.	.	.	.
Sublay	68 (68.69)	6 (37.50)	0.274 (0.091 – 0.820)	<b>0.02</b>	0.287 (0.089 - 0.925)	<b>0.03</b>
Underlay	29 (29.29)	8 (50.00)	2.414 (0.827 – 7.046)	0.10	2.306 (0.723 - 7.359)	0.16

SSI: Surgical Site Infection; SD: Standard deviation; 95% CI; 95% Confidence Interval; ASA: American Society of Anesthesiologists; BMI: Body Mass Index; VHWG: Ventral Hernia Working Group



## Figures

Figure 1: Recommendation of the type of prosthesis to use depending on the VHWG ventral hernia classification (3) \* P = prosthesis; GI: gastrointestinal

Figure 2: Flow diagram of the study population

Figure 3: Recurrence-free survival curves for ventral hernia as a function of the type of prosthesis used (Kaplan-Meier)

<b>Grade 1</b> <i>Low risk</i>	<b>Grade 2</b> <i>Co-Morbid</i>	<b>Grade 3</b> <i>Potentially contaminated</i>	<b>Grade 4</b> <i>Infected</i>
<ul style="list-style-type: none"> <li>• Low risk of complications</li> <li>• No history of wound infection</li> </ul>	<ul style="list-style-type: none"> <li>• Smoker</li> <li>• Obese</li> <li>• Diabetic</li> <li>• Immunosuppressed</li> <li>• COPD</li> </ul>	<ul style="list-style-type: none"> <li>• Previous wound infection</li> <li>• Stoma present</li> <li>• Violation of GI tract</li> </ul>	<ul style="list-style-type: none"> <li>• Infected mesh</li> <li>• Septic dehiscence</li> </ul>
all types of prostheses <i>Level of evidence: C</i>	Synthetic P: at risk Biologic P: recommended <i>Level of evidence: B</i>	Synthetic P: not recommended Biologic P: recommended <i>Level of evidence: B</i>	Synthetic P: not recommended Biologic P: recommended <i>Level of evidence: A</i>




Figure 3: Recurrence-free survival curves for ventral hernia as a function of the type of prosthesis used (Kaplan-Meier)

